Chewy (NYSE:CHWY) has recently become what some would consider to be a meme stock. On June 24, influential investor Keith Gill, also known as Roaring Kitty, disclosed the purchase of 9 million shares, valued at roughly $245 million. This sent investors flooding into the stock, artificially inflating its share price. However, shares have returned to their previous level before the news was reported due to its overall volatility. Even with the recent increase in its share price, Chewy has still been down 34% over this past year. CHWY, among other meme stocks, experiences wild price action swings, making short-term returns unpredictable. Investors who may be looking to start investing in Chewy should consider these other pet-centric stocks that have been performing much better recently. Below, these pet stocks have seen share price growth this past year, while Chewy has experienced a relatively rapid decline. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Zoetis (ZTS) a magnifying glass enlarges the Zoetis logo on a website Source: Casimiro PT / Shutterstock.com Zoetis (NYSE:ZTS) manufactures animal health medications, other products, and services. Its pharmaceutical products are used by livestock and domestic pets such as dogs and cats. Over this past year, its share price has risen by 3%. On May 2, Zoetis released its earnings for the first quarter of 2024, in which it stated that total revenue increased by 10% to $2.2 billion and net income rose by 9% year-over-year. Full-year guidance for 2024 anticipates revenue growth between 9.5% and 10.5%. Zoetis offers a dividend yield of 0.99% on an annual basis. The most recent quarterly distribution was for forty-three cents per share, paid out to investors on April 17. Zoetis is a pet stock that has outperformed Chewy over the past year. ZTS is also experiencing improved growth in both its domestic and international segments. Its recent purchase of a manufacturing facility in Australia and the expansion of its primary distribution hub in Lee’s Summit, Missouri, may lead to continued upside potential in the future. Freshpet (FRPT) A view of several packages of FreshPet (FRPT) pet food, on display at a local grocery store. Source: The Image Party / Shutterstock.com FreshPet (NASDAQ:FRPT) is a company that manufactures and sells natural and fresh treats and food for dogs and cats. It sells its products online, in retail stores, and in grocery stores. Over the past year, its share price has more than doubled due to strong earnings results and raised guidance. On May 6, FreshPet reported earnings for the first quarter of 2024, stating that total sales increased by 34% year-over-year. A net loss of $25 million was reported for Q1 2023, which improved to a net income of $18 million for Q1 2024. Improved guidance was reported, with anticipated revenue for the full year 2024 of $950 million, a 23% increase compared to 2023. FreshPet beat analyst predictions regarding earnings for the first quarter of 2024 primarily due to lower manufacturing costs. FreshPet has experienced outstanding growth this past year, while Chewy has struggled. FreshPet is a much better alternative. With its sorting momentum, FreshPet could continue to reward investors. PetIQ (PETQ) a smiling dog on a leash Source: Shutterstock PetIQ (NASDAQ:PETQ) offers pet health and wellness products under brands such as PetArmor, VetIQ, and Minties. It also operates veterinary services such as diagnostics testing, vaccinations, microchipping, and medications. On May 8, PETQ announced earnings for the first quarter of 2024, stating that total revenue increased by 6% and net income rose by 54% compared to the previous year. Robust demand for products such as flea and tick protection and other wellness-related products has increased earnings. Over this past year, its share price has risen by 51%. PETQ beat analyst expectations regarding its most recent earnings results, which has assisted in its share price appreciation. With record sales and increased efficiency in cost-saving methods in manufacturing, PETQ offers investors increased growth potential, while Chewy may still experience near-term issues. As of this writing, Noah Bolton did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article. Noah has about a year of freelance writing experience. He’s worked with Investopedia dealing with topics such as the stock market and financial news. More From InvestorPlace Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future” The post 3 Pet Stocks That Are Better Buys Than Chewy appeared first on InvestorPlace.
3 Pet Stocks That Are Better Buys Than Chewy
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...